A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs.
The SANAD trial

AG Marson,¹ R Appleton,² GA Baker,¹ DW Chadwick,¹ J Doughty,³ B Eaton,¹ C Gamble,⁴ A Jacoby,⁵ P Shackley,⁶ DF Smith,⁷ C Tudur-Smith,⁴ A Vanoli⁶ and PR Williamson⁴

¹ Division of Neurological Science, University of Liverpool, UK
² The Roald Dahl EEG Unit, Department of Neurology, Royal Liverpool Children’s NHS Trust (Alder Hey), Liverpool, UK
³ Institute of Health and Society, University of Newcastle, UK
⁴ Centre for Health Evaluation, University of Liverpool, UK
⁵ Division of Public Health, University of Liverpool, UK
⁶ School of Population and Health Sciences, University of Newcastle, UK
⁷ The Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool, UK

* Corresponding author

Executive summary

Health Technology Assessment 2007; Vol. 11: No. 37

Health Technology Assessment
NHS R&D HTA Programme
www.hta.ac.uk
Executive summary: Longer-term outcomes of standard versus new antiepileptic drugs

Background

Epilepsy is a common disorder (prevalence 0.5–1%) that is associated with varied prognosis but with considerable consequences for quality of life (QoL) and costs for society. The primary form of treatment is pharmacological. Current National Institute for Health and Clinical Excellence (NICE) guidelines for the treatment of epilepsy identify carbamazepine and valproate as being first-choice treatments.

Objectives

The aims of the study were to compare clinicians’ choice of one of the standard drug treatments (carbamazepine or valproate) versus appropriate comparator new drugs in patients who are managed with single drug treatment and to examine outcomes of treatment with regard to seizure recurrence, QoL impairments, chronic epilepsy and the cost-effectiveness of medical management strategies.

Design

The study was a pragmatic, randomised, unmasked, parallel group clinical trial comprising two arms, one comparing new drugs with carbamazepine and the other comparing new drugs with valproate.

Setting

This was a multicentre study recruiting patients with epilepsy from hospital outpatient clinics. At least 90% of new treatments of epilepsy would be expected to be initiated in this setting.

Participants

Patients with an adequately documented history of two or more clinically definite unprovoked epileptic seizures within the last year for whom treatment with a single antiepileptic drug represented the optimal therapeutic option were recruited. The study did not recruit children under the age of 5 years, those with acute symptomatic seizures or those who had a history of progressive seizures or those who had a history of progressive neurological or medical disease.

Interventions

Arm A was carbamazepine (CBZ) versus gabapentin (GBP) versus lamotrigine (LTG) versus oxcarbazepine (OXC) versus topiramate (TPM) and Arm B valproate (VPS) versus LTG versus TPM. When clinicians felt that CBZ was the optimal standard drug, patients were allocated to Arm A, and when VPS was the optimal drug they were allocated to Arm B. In both arms, guidelines were given as to initial dosing, but choice of dose and variation in dose with seizure response and adverse events were at the discretion of the clinician.

Main outcome measures

Primary outcome measures
1. Time to treatment failure (withdrawal of the randomised drug for reasons of unacceptable adverse events or inadequate seizure control or a combination of the two).
2. Time to achieve a 12-month remission of seizures.

Secondary outcome measures
1. Clinical outcomes: time from randomisation to first seizure, 24-month remission of seizures, incidence of clinically important adverse events.
2. QoL outcomes.
3. Health economic outcomes.

Results

A total of 1721 patients were recruited to Arm A and 716 to Arm B. Arm A recruited 88% of patients with symptomatic or cryptogenic partial epilepsy and 10% with unclassified epilepsy. Arm B recruited 63% of patients with idiopathic generalised epilepsy and 25% with unclassified epilepsy.
Arm A
LTG had the lowest incidence of treatment failure and was statistically superior to all drugs for this outcome with the exception of OXC. Some 12% and 8% fewer patients experienced treatment failure on LTG than CBZ, the standard drug, at 1 and 2 years after randomisation, respectively. The superiority of LTG over CBZ was due to its better tolerability but there is satisfactory evidence indicating that LTG is not clinically inferior to CBZ for measures of its efficacy (treatment failure due to inadequate seizure control and time to achieving a 12-month remission). No consistent differences in QoL outcomes were found between treatment groups, although patients achieving a 12-month remission by 2 years after randomisation had superior QoL outcomes to those who had not, and patients who had experienced a treatment failure outcome exhibited poorer QoL than those who remained on their randomised treatment. Health economic analysis supported LTG being preferred to CBZ for both cost per seizure avoided and cost per quality-adjusted life-year gained.

Arm B
For time to treatment failure, VPS, the standard drug, was preferred to both TPM and LTG. VPS was the drug least likely to be associated with treatment failure for inadequate seizure control and was the preferred drug for time to achieving a 12-month remission. QoL assessments did not show any between-treatment differences, though patients achieving a 12-month remission by 2 years after randomisation had superior QoL outcomes to those who had not and patients who had experienced a treatment failure outcome exhibited poorer QoL. The health economic assessment supported the conclusion that VPS should remain the drug of first choice for idiopathic generalised or unclassified epilepsy, although there is a suggestion that TPM is a cost-effective alternative to VPS.

Conclusions
Implications for healthcare
The study provides evidence that LTG may be a clinical and cost-effective alternative to the existing standard drug treatment, CBZ. Some 88% of patients in Arm A were diagnosed as having partial seizures, so conclusions are applicable to patients with these epilepsy syndromes. For patients in Arm B with idiopathic generalised epilepsy or difficult to classify epilepsy, VPS remains the clinically most effective drug, although TPM may be a cost-effective alternative for some patients.

It should be noted that the SANAD trial was not designed to address the issue of safety during pregnancy, an important factor for choice of antiepileptic drugs in women during their childbearing years.

Recommendations for research
Since the design and start of the trial, three new antiepileptic drugs have been licensed in the UK for the treatment of epilepsy (levetiracetam, zonisamide and pregabalin). It will be important that these drugs are compared in a similarly designed trial with LTG and OXC and also with VPS.

Publication
The Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender.

Secondly, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Thirdly, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer-reviewed by a number of independent expert referees before publication in the widely read monograph series Health Technology Assessment.

Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this monograph was commissioned by the HTA Programme as project number 95/13/01. The contractual start date was in September 1998. The draft report began editorial review in June 2006 and was accepted for publication in April 2007. As the funder, by devising a commissioning brief, the HTA Programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley
Series Editors: Dr Aileen Clarke, Dr Peter Davidson, Dr Chris Hyde,
Dr John Powell, Dr Rob Riemsma and Professor Ken Stein
Programme Managers: Sarah Llewellyn Lloyd, Stephen Lemon, Stephanie Russell
and Pauline Swinburne